Table 1.

Characteristics of all patients in the CRLMx cohort (n = 62)

		n	(%)
No. of patients		62	100.0
Age in years a		62.0	±8.2
Gender	Male	40	64.5
	Female	22	35.5
Localisation of primary tumour	Colon	13	21.0
	Caecum	4	6.5
	Sigma	12	19.4
	Rectum	33	53.2
UICC stadium of primary tumour	I	4	6.5
	II	5	8.1
	III	20	32.3
	IV	31	50.0
	Unknown	2	3.2
MSKCC score	0	6	9.7
	I	7	11.3
	II	16	25.8
	III	29	46.8
	IV	4	6.5
	V	0	0.0
Positive lymph node of primary tumour	Yes	44	71.0
	No	15	24.2
	Unknown	3	4.8
DFS interval  <12 months	Yes	39	62.9
	No	23	37.1
No. of metastases	1	23	37.1
	>1	34	54.8
	Unknown	5	8.1
Size of metastases	≤5 cm	38	61.3
	>5 cm	20	32.3
	Unknown	4	6.5
Preoperative CEA-value [ng/ml]	≤200	56	90.3
	>200	5	8.1
	Unknown	1	1.6
Time point of metastases	Synchronousc	30	48.4
	Metachronous	32	51.6
ASA	I	2	3.2
	II	32	51.6
	III	28	45.2
	IV	0	0.0
Adipositas (BMI ≥ 25)	Yes	31	50.0
	No	30	48.4
	Unknown	1	1.6
Diabetes	Yes	9	14.5
	No	53	85.5
Alcohol	Yes	12	19.4
	No	49	79.0
	Unknown	1	1.6
Hepato-toxic medication	Yes	46	74.2
	No	16	25.8
Neoadjuvant chemotherapy	Yes	27	43.5
	No	33	53.2
	Unknown	2	3.2
Adjuvant chemotherapy	Yes	55	88.7
	No	7	11.3
PDK4 mRNA expression	Transcripts ≤ median	26	41.9
	Transcripts > median	26	41.9
	Missing values	10	16.1
OS in months b		62.8	±40.9

ASA American Society of Anaesthesiologists, DFS disease-free survival, MSKCC Memorial Sloan-Kettering Cancer Center, OS overall survival, PDK pyruvate dehydrogenase kinase, UICC Union for International Cancer Control

^aData are given as median ± standard deviation

^bData are given as mean ± standard deviation

^cDiagnosed before or within 3 months after resection of the primary tumour